Insider Selling: Sight Sciences (NASDAQ:SGHT) EVP Sells $220,088.40 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT – Get Free Report) EVP Brenton Taylor sold 20,685 shares of Sight Sciences stock in a transaction on Monday, November 16th. The shares were sold at an average price of $10.64, for a total transaction of $220,088.40. Following the completion of the sale, the executive vice president directly owned 241,305 shares of the company’s stock, valued at approximately $2,567,485.20. This trade represents a 7.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Brenton Taylor also recently made the following trade(s):

  • On Friday, October 2nd, Brenton Taylor sold 2,988 shares of Sight Sciences stock. The stock was sold at an average price of $8.85, for a total transaction of $26,443.80.

Sight Sciences Price Performance

SGHT stock opened at $10.18 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 5.04 and a quick ratio of 4.72. The company’s 50-day moving average is $9.21 and its 200-day moving average is $6.31. The stock has a market capitalization of $565.80 million, a PE ratio of -19.58 and a beta of 2.44. Sight Sciences, Inc. has a 1 year low of $3.38 and a 1 year high of $11.60.

Sight Sciences (NASDAQ:SGHT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). The business had revenue of $24.92 million for the quarter, compared to the consensus estimate of $23.55 million. Sight Sciences had a negative return on equity of 43.91% and a negative net margin of 32.13%. Equities research analysts expect that Sight Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors and hedge funds have recently made changes to their positions in SGHT. Pathstone Holdings LLC boosted its stake in Sight Sciences by 30.2% during the 3rd quarter. Pathstone Holdings LLC now owns 2,186,524 shares of the company’s stock valued at $20,466,000 after purchasing an additional 507,544 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Sight Sciences in the second quarter worth approximately $16,710,000. Goldman Sachs Group Inc. raised its stake in shares of Sight Sciences by 38.9% in the third quarter. Goldman Sachs Group Inc. now owns 278,044 shares of the company’s stock worth $2,602,000 after purchasing an additional 77,917 shares during the last quarter. Royce & Associates LP purchased a new stake in shares of Sight Sciences in the third quarter worth approximately $1,676,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Sight Sciences by 13.4% in the first quarter. Dimensional Fund Advisors LP now owns 341,681 shares of the company’s stock valued at $1,288,000 after purchasing an additional 40,346 shares in the last quarter. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on SGHT. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a report on Wednesday, November 4th. UBS Group increased their target price on Sight Sciences from $8.00 to $13.50 and gave the stock a “buy” rating in a report on Thursday, November 12th. Citigroup lifted their price target on shares of Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Monday, October 5th. Piper Sandler reissued an “overweight” rating and issued a $12.00 price target (up from $9.00) on shares of Sight Sciences in a research report on Thursday, November 5th. Finally, Wall Street Zen lowered shares of Sight Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 14th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $10.31.

View Our Latest Report on SGHT

Sight Sciences Company Profile

(Get Free Report)

Sight Sciences is a medical technology company that develops and commercializes devices for ophthalmic care, with a focus on glaucoma and dry eye disease. Its products are designed to support minimally invasive procedures and address underlying causes of these conditions. The company’s portfolio includes the OMNI Surgical System, used in procedures to reduce eye pressure in patients with glaucoma, and TearCare, a device-based treatment for evaporative dry eye associated with meibomian gland dysfunction.

Recommended Stories

Insider Buying and Selling by Quarter for Sight Sciences (NASDAQ:SGHT)

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.